Two clinical phenotypes in polycythemia vera

New England Journal of Medicine

Volumn 371, Issue 9, 2014, Pages 808-817

  Spivak, Jerry L ^a   Considine, Michael ^b   Williams, Donna M ^a   Talbot Jr , Conover C ^a   Rogers, Ophelia ^a   Moliterno, Alison R ^a   Jie, Chunfa ^c   Ochs, Michael F ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d The College of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HEMOGLOBIN; JANUS KINASE 2;

ACCURACY; ADULT; AGE; AGED; ALLELE; ARTICLE; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; DRUG EXPOSURE; EXTRACELLULAR MATRIX; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; JAK2 GENE; LEUKOCYTE COUNT; MALE; MALIGNANT TRANSFORMATION; NEUTROPHIL; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SEX DIFFERENCE; SPLENECTOMY; SPLENOMEGALY; SURVIVAL; THROMBOCYTE COUNT; THROMBOEMBOLISM; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BLOOD CELL COUNT; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYCYTHEMIA VERA; SEX FACTORS;

EID: 84907379826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1403141     Document Type: Article

References (39)

1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Stein BL, Williams DM, Wang NY, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010;95:1090-7.
3. Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010;16:4339-52.
4. Catani L, Zini R, Sollazzo D, et al. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 2009;23:997-1000.
5. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32-8.
6. Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011;118:1610-21.
7. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9.
8. Videbaek A. Polycythaemia vera: course and prognosis. Acta Med Scand 1950;138:179-87.
9. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997;102:14-20.
10. Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011;2011:874146.
11. Wasserman LR. The management of polycythaemia vera. Br J Haematol 1971;21:371-6.
12. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913-5.
13. Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008;36:1480-6.
14. Slezak S, Jin P, Caruccio L, et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med 2009;7:39.
15. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-84.
16. Silverstein MN. Postpolycythemia myeloid metaplasia. Arch Intern Med 1974;134:113-7.
17. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:2794-9.
18. Gangat N, Strand J, Lasho TL, et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008;80:197-200.
19. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y. Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat Cell Biol 2004;6:547-54.
20. Wall DS, Mears AJ, McNeill B, et al. Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity. J Cell Biol 2009;184:101-12.
21. Lee JH, Suk J, Park J, et al. Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol Cancer Res 2009;7:1663-71.
22. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010;18:268-81.
23. Wang J, Leclercq I, Brymora JM, et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009;137:713-23.
24. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012;185:537-46.
25. Koli K, Ryynänen MJ, Keski-Oja J. Latent TGF-beta binding proteins (LTBPs)-1 and -3 coordinate proliferation and osteogenic differentiation of human mesenchymal stem cells. Bone 2008;43:679-88.
26. Daniel C, Wiede J, Krutzsch HC, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004;65:459-68.
27. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Ge-nome- wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009;69:709-17.
28. Shibata S, Ishiyama J. Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-β and is required for TGF-β-induced hydrogen peroxide production in fibroblasts. Fibrogenesis Tissue Repair 2013;6:6.
29. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999;10:790-5.
30. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-14.
31. Huang Y, Sitwala K, Bronstein J, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012;119:388-98.
32. Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009;69:1343-9.
33. Ridnour LA, Barasch KM, Windhausen AN, et al. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS One 2012;7(9):e44081.
34. Rosário M, Paterson HF, Marshall CJ. Activation of the Ral and phosphatidylinositol 3′ kinase signaling pathways by the ras-related protein TC21. Mol Cell Biol 2001;21:3750-62.
35. Rosário M, Paterson HF, Marshall CJ. Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells. EMBO J 1999;18:1270-9.
36. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
37. Tripodo C, Sangaletti S, Guarnotta C, et al. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 2012;120:3541-54.
38. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013;13:285-99.
39. Yuwaraj S, Ding J, Liu M, Marsden PA, Levy GA. Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. Genomics 2001;71:330-8.